Literature DB >> 32800967

Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?

Adaya Weissler-Snir1, Paul Dorian2, Harry Rakowski3, Melanie Care3, Danna Spears3.   

Abstract

BACKGROUND: Identifying patients with hypertrophic cardiomyopathy (HCM) who warrant a primary prevention implantable cardioverter-defibrillator (ICD) is crucial. ICDs are effective in terminating life-threatening arrhythmias; however, ICDs carry risks of complications.
OBJECTIVE: The purpose of this study was to assess the incidence and predictors of appropriate ICD therapies, inappropriate shocks, and device-related complications in patients with HCM and primary prevention ICDs.
METHODS: All patients with HCM who underwent primary prevention ICD implantation at Toronto General Hospital between September 2000 and December 2017 were identified. Therapies (shocks or antitachycardia pacing) for ventricular tachycardia >180 beats/min or ventricular fibrillation were considered appropriate.
RESULTS: Three hundred two patients were followed for a mean 6.1 ± 4.3 years (1801 patient-years of follow-up). Thirty-eight patients (12.6%) received at least 1 appropriate ICD therapy (2.3%/y); the 5-year cumulative probability of receiving appropriate ICD therapy was 9.6%. None of the conventional risk factors nor the European Society of Cardiology risk score was associated with appropriate ICD therapy. In multivariable analysis, age < 40 years at implantation and atrial fibrillation were independent predictors of appropriate ICD therapy. In a subgroup of patients who had undergone cardiac magnetic resonance imaging before ICD implantation, severe late gadolinium enhancement was the strongest predictor of appropriate ICD therapies. ICD-related complications or inappropriate shocks occurred in 87 patients (28.8%), with an inappropriate shock rate of 2.1%/y; the 5-year cumulative probability was 10.7%.
CONCLUSION: The incidence of appropriate ICD therapies in patients with HCM and primary prevention ICDs is lower than previously reported; a high proportion of patients suffer from an ICD-related complication. Traditional risk factors have low predictive utility. Severe late gadolinium enhancement, atrial fibrillation, and young age are important predictors of ventricular tachyarrhythmias in HCM.
Copyright © 2020 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Appropriate implantable cardioverter-defibrillator therapy; Hypertrophic cardiomyopathy; Primary prevention implantable cardioverter-defibrillator; Sudden cardiac death; Ventricular arrhythmia

Year:  2020        PMID: 32800967     DOI: 10.1016/j.hrthm.2020.08.009

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  3 in total

1.  Assessment of dynamic cardiac repolarization and contractility in patients with hypertrophic cardiomyopathy.

Authors:  Andrew E Radbill; Lucy Y Lei; Sachin Y Paranjape; Daniel J Blackwell; Robert L Abraham; Derek S Chew; Satish R Raj; Björn C Knollmann
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

Review 2.  Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy.

Authors:  Darson Du; Christopher O Y Li; Kevin Ong; Ashkan Parsa; Adaya Weissler-Snir; Jeffrey B Geske; Zachary Laksman
Journal:  CJC Open       Date:  2022-01-07

Review 3.  Ventricular arrhythmia and sudden cardiac death in hypertrophic cardiomyopathy: From bench to bedside.

Authors:  Hua Shen; Shi-Yong Dong; Ming-Shi Ren; Rong Wang
Journal:  Front Cardiovasc Med       Date:  2022-08-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.